Hepatitis C New Drugs Review
24.1K views | +3 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

Hepatitis Drugs and Vaccines: World Market 2013-2023

Hepatitis Drugs and Vaccines: World Market 2013-2023 MarketWatch (press release) Our study forecasts individual revenues of 10 top products:- Baraclude- Zeffix- Hepsera- Viread- Tyzeka- Engerix-B/Havrix/Twinrix/Fendrix- Pegasys- Incivek- PegIntron-...
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Drug–Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction

Drug–Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction | Hepatitis C New Drugs Review | Scoop.it

Abstract Substance use and pharmacologic treatment of co-occurring infections such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are associated with many adverse consequences including pharmacokinetic and pharmacodynamic drug–drug interactions (DDIs). The National Institute on Drug Abuse sponsored a 2-day conference on DDIs at which clinicians/scientists from government, academia, and the pharmaceutical industry presented the most current research findings to formulate a comprehensive overview of DDIs. Specific topics discussed included drug metabolism; drug interactions between medications used in the treatment of HIV, HCV, and substance use disorders; intrahepatic concentrations and methods of assessment of drugs in liver disease of varying etiologies and degrees of impairment; and minimally invasive sampling techniques for the assessment of intrahepatic drug concentrations, viral replication, and changes in gene expression in response to treatment. Finally, the speakers identified research targets and priorities on DDIs. Areas of emphasis included development of diagnostic assays for drug concentration assessment in different organs, an enhanced understanding of factors responsible for alterations in drug metabolism and excretion, and establishment of clinical trials and work groups to study DDIs. Our long-term objective is to broaden investigation in the field of DDIs in substance users.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse | Hepatitis C New Drugs Review | Scoop.it
AbbVie's 3 direct‐acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C viru
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy

Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy | Hepatitis C New Drugs Review | Scoop.it
Chronic hepatitits B virus remains a public health challenge, infecting more than 240 million people globally and causing 600,000 deaths per year from end‐stage liver disease and/or hepatocellula
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines | Hepatitis C New Drugs Review | Scoop.it
Background Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC. The majority of advanced HCC patients are resistant to sorafenib. The mechanisms of sorafenib resistance are still unknown. Methods The expression of molecules involved in the mitogen-activated protein kinase (MAPK) signaling pathway in human hepatoma cell lines was examined in the presence or absence of sorafenib. Apoptosis of human hepatoma cells treated with sorafenib was investigated, and the expression of Jun proto-oncogene (c-Jun) was measured. Results The expression and phosphorylation of c-Jun were enhanced in human hepatoma cell lines after treatment with sorafenib. Inhibiting c-Jun enhanced sorafenib-induced apoptosis. The overexpression of c-Jun impaired sorafenib-induced apoptosis. The expression of osteopontin, one of the established AP-1 target genes, was enhanced after treatment with sorafenib in human hepatoma cell lines. Conclusions The protein c-Jun plays a role in sorafenib resistance in human hepatoma cell lines. The modulation and phosphorylation of c-Jun could be a new therapeutic option for enhancing responsiveness to sorafenib. Modulating c-Jun may be useful for certain HCC patients with sorafenib resistance.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis Delta

Hepatitis Delta | Hepatitis C New Drugs Review | Scoop.it
Hepatitis Delta is the most severe form of viral hepatitis in humans and is caused by infection with the hepatitis delta virus (HDV). HDV can be acquired either by co-infection (a simultaneous co-infection with HDV and HBV) or by super-infection (infection of someone already harboring a chronic HBV infection). Although HDV/HBV simultaneous co-infection in adults
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma

Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma | Hepatitis C New Drugs Review | Scoop.it
The journal focuses on all topics related to hepatoma.Articles in the following areas are especially welcome: Pathogenesis, clinical examination and diagnosis of hepatoma; Complications of hepatoma, and their preventions and treatments etc.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

FDA-approved all oral DAA regimens show high cure rate for hepatitis C

FDA-approved all oral DAA regimens show high cure rate for hepatitis C | Hepatitis C New Drugs Review | Scoop.it
FDA-approved oral direct-acting antiviral (DAA) regimens produce high sustained virologic response (SVR) rates for all six hepatitis C virus (HCV) genotypes and for patient populations historically considered difficult t
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Roles for Cell-Cell Adhesion and Contact in Obesity-Induced Hepatic Myeloid Cell Accumulation and Glucose Intolerance

Roles for Cell-Cell Adhesion and Contact in Obesity-Induced Hepatic Myeloid Cell Accumulation and Glucose Intolerance | Hepatitis C New Drugs Review | Scoop.it
Highlights •Obesity enhances VLA-4-dependent cell-cell adhesion between LSEC and myeloid cells •VLA-4 blockade improves hyperglycemia in obese mice •Cell-cell contact between leukocytes and hepatocytes promotes gluconeogenesis
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C in Developing Countries: Current and Future Challenges

Hepatitis C in Developing Countries: Current and Future Challenges | Hepatitis C New Drugs Review | Scoop.it
Download PDF eBook Hepatitis C in Developing Nations: Current and Future Challenges, Hepatitis C in Developing Nations: Current and Future Challenges explores the present state of HCV in a number of international locations, together
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Path to Zero - By The Economist Intelligence Unit - Sponsored by Abbvie

Path to Zero - By The Economist Intelligence Unit - Sponsored by Abbvie | Hepatitis C New Drugs Review | Scoop.it
Our foundational research, tools and report strive to build focus and accountability towards eliminating HCV. These materials and highlights of three expert Roundtable discussions in a report and video aim to spark debate and actionable recommendations on HCV policy, access to care and equity.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years

Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years | Hepatitis C New Drugs Review | Scoop.it
Silymarin is the extract of Silybum marianum, or milk thistle, and its major active compound is silybin, which has a remarkable biological effect. It is used in different liver disorders, particularly chronic liver diseases, cirrhosis and hepatocellular carcinoma, because of its antioxidant, anti-inflammatory and antifibrotic power. Indeed, the anti-oxidant and anti-inflammatory effect of silymarin is oriented towards the reduction of virus-related liver damages through inflammatory cascade softening and immune system modulation. It also has a direct antiviral effect associated with its intravenous administration in hepatitis C virus infection. With respect to alcohol abuse, silymarin is able to increase cellular vitality and to reduce both lipid peroxidation and cellular necrosis. Furthermore, silymarin/silybin use has important biological effects in non-alcoholic fatty liver disease. These substances antagonize the progression of non-alcoholic fatty liver disease, by intervening in various therapeutic targets: oxidative stress, insulin resistance, liver fat accumulation and mitochondrial dysfunction. Silymarin is also used in liver cirrhosis and hepatocellular carcinoma that represent common end stages of different hepatopathies by modulating different molecular patterns. Therefore, the aim of this review is to examine scientific studies concerning the effects derived from silymarin/silybin use in chronic liver diseases, cirrhosis and hepatocellular carcinoma.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα

Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα | Hepatitis C New Drugs Review | Scoop.it
Objective Chronic HCV infection is characterised by innate immune activation with increased interferon-stimulated genes (ISG) expression and by an altered phenotype of interferon-responsive natural killer (NK) cells. Here, we asked whether a rapid reduction in viremia by daclatasvir (DCV) and asunaprevir (ASV) improves the response to pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy.

Design Twenty-two HCV-infected non-responders to previous PegIFN/RBV therapy were studied for IFN-responsiveness of NK cells during quadruple (QUAD) therapy with DCV, ASV, PegIFN and RBV. A direct comparison of early NK cell responses in PegIFN/RBV therapy and QUAD therapy was performed for seven patients using paired cryopreserved peripheral blood mononuclear cells (PBMC) from both treatment courses. As a validation cohort, nine DCV/ASV-treated patients were studied for their NK cell response to in vitro stimulation with IFNα.

Results The 24 h virological response to QUAD therapy correlated with an increase in signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1 (pSTAT1) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in NK cells, and the STAT1/pSTAT1/TRAIL induction was greater during QUAD therapy than during previous PegIFN/RBV therapy. Successful QUAD therapy as well as successful IFN-free DCV/ASV regimen resulted in an improved functional NK cell response (degranulation and TRAIL expression) to in vitro stimulation with IFNα.

Conclusions IFN-responsiveness can be improved by inhibiting HCV replication and reducing the HCV-induced activation of the innate immune response. This may provide a rationale for clinical trials of a brief period of direct acting antiviral therapy followed by PegIFN/RBV therapy to reduce the overall treatment costs in low-income and middle-income countries.

Trial registration numbers NCT01888900 and [NCT00718172][1].

[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00718172&atom=%2Fgutjnl%2F66%2F4%2F724.atom
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology | Hepatitis C New Drugs Review | Scoop.it
Although the importance of the liver in clinical pharmacology is widely recognized, little is known in humans concerning its function in vivo at the hepatocyte level and how pharmacological function
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Liver Disease and Fibrosis Assessment in Substance Use–Related Disorders

Liver Disease and Fibrosis Assessment in Substance Use–Related Disorders | Hepatitis C New Drugs Review | Scoop.it
Substance users have the highest prevalence of hepatitis C virus (HCV) infection but have rarely been treated, largely because of their mistrust of the health care system, misconceptions about th
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution

Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution | Hepatitis C New Drugs Review | Scoop.it
Asunaprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, demonstrating efficacy in clinical studies in patients infected with HCV genotype 1 or 4, with eithe
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions

Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions | Hepatitis C New Drugs Review | Scoop.it
Approximately 170 million people harbor chronic infection with hepatitis C virus (HCV) worldwide, with 3–4 million in the United States. As recently as 2013, the few treatment options available wer
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Eiger Biopharma SARASAR® (lonafarnib)

Eiger Biopharma SARASAR® (lonafarnib) | Hepatitis C New Drugs Review | Scoop.it
Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cellular process inside liver cells to complete a key step in its life cycle.  Lonafarnib inhibits the prenylation step of HDV replication and blocks the ability of the
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma

Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma | Hepatitis C New Drugs Review | Scoop.it
Article
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review | Hepatitis C New Drugs Review | Scoop.it
Data Synthesis: Six DAA regimens showed high sustained virologic response (SVR) rates (>95%) in patients with HCV genotype 1 infection without cirrhosis, including those with HIV co-infection. Effective treatments for HCV genotype 3 infection are limited (2 DAA regimens). Patients with hepatic decompensation, particularly those with Child–Turcotte–Pugh class C disease, had lower SVR rates (78% to 87%) than other populations. The addition of ribavirin was associated with increased SVR rates for certain DAA regimens and patient groups. Overall rates of serious adverse events and treatment discontinuation were low (<10% in the general population); regimens that included ribavirin had more mild or moderate adverse events than those without.

Twenty-three studies had moderate risk of bias (10 were open-label single-group trials, 11 had limited information on concealment of the allocation scheme, and 5 had selective outcome reporting). All but 1 of the studies were industry-funded. Heterogeneity of interventions precluded pooling. 

 Conclusion: Multiple oral DAA regimens show high rates of safety, tolerability, and efficacy for treatment of HCV genotype 1 infection, particularly among persons without cirrhosis. 

 Primary Funding Source: Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42014009711)
Krishan Maggon 's insight:
Published: Ann Intern Med. 2017. DOI: 10.7326/M16-2575
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cyclooxygenase‐2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents

Cyclooxygenase‐2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents | Hepatitis C New Drugs Review | Scoop.it
Cyclooxygenase-2 (COX-2) is one of the important mediators of inflammation in response to viral infection, and it contributes to viral replication, for example, cytomegalovirus or hepatitis C virus replication.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C mutations 'outrun' immune systems, lab study shows

Hepatitis C mutations 'outrun' immune systems, lab study shows | Hepatitis C New Drugs Review | Scoop.it
Unlike its viral cousins hepatitis A and B, hepatitis C virus (HCV) has eluded the development of a vaccine and infected more than 170 million people worldwide. Now, researchers at Johns Hopkins Medicine report that a nove
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Merck’s Uprifosbuvir Faces Fight to be Profitable in Declining Hepatitis C Market - Pharma Integrates 2017

Merck’s Uprifosbuvir Faces Fight to be Profitable in Declining Hepatitis C Market - Pharma Integrates 2017 | Hepatitis C New Drugs Review | Scoop.it
Owing to various setbacks and adverse market dynamics, Merck & Co.’s newest direct-acting antiviral (DAA) for hepatitis C, uprifosbuvir, will represent only a minor player in the hepatitis C market by 2025, according to research and consulting firm GlobalData. In a recent Form 8-K filing submitted to the US Securities and Exchange Commission, Merck announced the …
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead's Limbo: How Low Can It Go?

Gilead's Limbo: How Low Can It Go? | Hepatitis C New Drugs Review | Scoop.it
Gilead did the $80's in 3 months. Gilead did the $70's in 6+ months. Pressed by an insolent analyst letter and incessant deal rumors, Gilead is doing the $60's
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Patient Safety: What You Can Do to Be a Safe Patient | HAI | CDC

Patient Safety: What You Can Do to Be a Safe Patient | HAI | CDC | Hepatitis C New Drugs Review | Scoop.it
Patient Safety Awareness Week is March 12th - 18th. Learn more about what you can do to be a safe patient: https://t.co/WfFBmw0HDa @CDCgov
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New perspectives for research on hepatitis C virus

New perspectives for research on hepatitis C virus | Hepatitis C New Drugs Review | Scoop.it
The hepatitis C virus (HCV) infects around 160 million people. Although there are new therapies, HCV infection is one of the most common causes of liver transplantation as these new drugs are very expensive and not used extensively. Also vaccination against HCV is currently impossible. Scientists at the TWINCORE are now investigating a very close relative of the hepatitis C virus: the "non-primate hepacivirus", (NPHV). This newly discovered viral pathogen infects horses and donkeys and raises questions that will give new insights about the human hepatitis C virus. In a recent study, published in PNAS, the researchers have focused on immune control of NPHV in its natural host, the horse.
more...
No comment yet.